Skip to content

Enterprise value at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$622.06B+50.5%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$2.28B+84.0%
Nuvation Bio logo
Nuvation BioNUVB
$1.42B+154%
Immunome logo
ImmunomeIMNM
$1.9B+470%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2.62B+275%
Erasca, Inc. logo
Erasca, Inc.ERAS
$5.03B+1,265%

Other financials

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%
Total assets$349.3M+62.1%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation

See full
Market cap$1.57B+62.1%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0.0×
Current ratio14×-0.4×

Where this comes from

Calculated from ArriVent BioPharma, Inc.’s reported figures.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s enterprise value?
ArriVent BioPharma, Inc. (AVBP) reported enterprise value of $958.05M in Q1 2026.
How has ArriVent BioPharma, Inc.'s enterprise value changed year-over-year?
ArriVent BioPharma, Inc.'s enterprise value increased by 65.4% year-over-year, from $579.23M to $958.05M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.